ARS Pharmaceuticals (SPRY) announced that the FDA has approved neffy 1 mg for the treatment of Type I Allergic Reactions, including anaphylaxis, in children who are aged 4 years and older and weigh 15 to less than 30 kilograms.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- ARS Pharmaceuticals Secures Major Formulary Wins, Strengthens Market Position for neffy
- Closing Bell Movers: Booking gains 3%, Akamai down 8% on earnings
- ARS Pharmaceuticals says OptumRx, Cigna, Navitus add neffy to formularies
- Amazon downgraded, Shopify upgraded: Wall Street’s top analyst calls
- ARS Pharmaceuticals initiated with an Outperform at Oppenheimer